Abstract
Replication-selective microbial agents hold promise as a novel cancer treatment platform. dl1520 (Onyx-015), an E1B-55 kD gene-deleted adenovirus, was the first such genetically engineered agent to be tested in humans. Over 200 cancer patients have been treated to date on over 10 clinical trials (phases I-III). The virus was generally well-tolerated at doses of up to 2 × 1012 particles by intratumoral, intraperitoneal, hepatic arterial and intravenous administration; no maximally tolerated doses were identified by any route of administration. Viral replication was tumor-selective, and was documented after administration by all routes; replication was generally transient (<10 days), however, and was variable depending on tumor histology. single agent efficacy has been limited to date (0–14% local tumor regression rates). in combination with chemotherapy, however, encouraging antitumoral activity has been demonstrated. these clinical research results demonstrate the potential of this novel treatment platform, as well as the hurdles to be overcome. novel replication-selective agents with improved potency are needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Merritt J et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung cancer and head and neck cancer Cancer Gene Ther 1997 4: S12 (Abstr.)
Nemunaitis J et al. Three phase II trials of intratumoral injection with a replication-deficient adenovirus carrying the p53 gene (AdCMV-p53) in patients with recurrent/refractory head and neck cancer Proc Am Soc Clin Oncol 1999 18: 1661
Kirn D . Replication-selective micro-organisms: fighting cancer with targeted germ warfare J Clin Invest 2000 105: 836–838
Heise C, Kirn D . Replication-selective adenviruses as oncolytic agents J Clin Invest 2000 105: 847–851
Pawelek J, Low K, Bermudes D . Tumor-targeted Salmonella as a novel anticancer vector Cancer Res 1997 57: 4537–4544
Heise C et al. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy Cancer Res 1999 59: 2623–2628
Kirn D . Selectively-replicating viruses as therapeutic agents against cancer. In: Gerschenson LA (ed.) Cancer Gene Therapy Vol. 1: Academic Press: San Diego 1998 pp 235–248
Smith R et al. Studies on the use of viruses in the treatment of carcinoma of the cervix Cancer 1956 9: 1211–1218
Webb HE, Smith CE . Viruses in the treatment of cancer Lancet 1970 1: 1206–1208
Asada T . Treatment of human cancer with mumps virus Cancer 1974 34: 1907–1928
Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856
Mineta T, Rabkin SD, Martuza RL . Treatment of malignantgliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant Cancer Res 1994 54: 3963–3966
Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943
Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells (see comments) Science 1996 274: 373–376
Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments) Nat Med 1997 3: 639–645
Lorence RM et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy Cancer Res 1994 54: 6017–6021
Van Pachterbeke C et al. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures Int J Cancer 1993 55: 672–677
Coffey M, Strong J, Forsyth P, Lee P . Reovirus therapy of tumors with activated ras pathway Science 1998 282: 1332–1334
Mastrangelo M, Eisenlohr L, Gomella L, Lattime E . Poxvirus vectors: orphaned and underappreciated J Clin Invest 2000 105: 1031–1034
Gromeier M et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma (see comments) Proc Natl Acad Sci USA 2000 97: 6803–6808
Stojdl DF et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 2000 6: 821–825
Wold WS, Hermiston TW, Tollefson AE . Adenovirus proteins that subvert host defenses Trends Microbiol 1994 2: 437–443
Sparer TE et al. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model J Virol 1996 70: 2431–2439
Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 1997 57: 2559–2563
Heise C, Williams A, Olesch J, Kirn D . Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects Cancer Gene Ther 1999 6: 499–504
Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856
Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943
Ganly I, Soutar D, Brown R, Kaye S . p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy Br Cancer 2000 82: 392–398
Scheffner M, Munger K, Byrne JC, Howley PM . The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc Natl Acad Sci USA 1991 88: 5523–5527
Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers Science 1991 253: 49–53
Harada J, Berk A . p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication J Virol 1999 73: 5333–5344
Reid T et al. Hepatic arterial infusion of a replication-selective adenovirus, Onyx-015: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 953 (Abstr.)
Kemeny N et al. Hepatic arterial infusion of chemotherapy following resection of hepatic metastases from colorectal cancer N Engl J Med 1999 341: 2039–2048
Ganly I et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806
Hecht JR et al. A phase I study of multiple direct injections of ONYX-015 adenovirus under endoscopic ultrasound guidance Proc Am Soc Clin Oncol 1999 18: 186 (Abstr.)
Hecht R et al. Endoscopic ultrasound-guided intratumoral injection of pancreatic carcinomas with a replication-selective adenovirus: a phase I/II clinical trial Proc Am Soc Clin Oncol 2000 19: 1039 (Abstr.)
Kirn DH et al. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Proc Am Soc Clin Oncol 1999 18: 1505 (Abstr.)
Vasey P et al. A phase I trial of an E1B-55kD gene-deleted adenovirus administered by intraperitoneal injection into patients with advanced, refractory ovarian carcinoma Proc Am Soc Clin Oncol 2000 19: 1512 (Abstr.)
Nemunaitis J, Cunningham C, Randlev B, Kirn D . A phase I trial of intravenous administration with a replication-selective adenovirus, dl 1520 Proc Am Soc Clin Oncol 2000 19: 724 (Abstr.)
Khuri F et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885
Reid A et al. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma EORTC-NCI-AACR Meeting on Molecular Therapeutics of Cancer 1999
Kirn D et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer Proc Am Soc Clin Oncol 1998 17: 391a
Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments) Nat Med 1997 3: 639–645
Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer (see comments) Nat Med 2000 6: 879–885
Goodrum FD, Ornelles DA . p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J Virol 1998 72: 9479–9490
Rothmann T et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells J Virol 1998 72: 9470–9478
Dobner T, Horikoshi N, Rubenwolf S, Shenk T . Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor Science 1996 272: 1470–1473
Yew PR, Liu X, Berk AJ . Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53 Genes Dev 1994 8: 190–202
Goodrum FD, Ornelles DA . The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle J Virol 1997 71: 548–561
Heise C et al. An E1A mutant adenovirus with potent and selective systemic antitumoral efficacy Nat Med 2000 6: 1134–1139
Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 1987 156: 107–121
Dobbelstein M et al. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence EMBO J 1997 16: 4276–4284
Gooding LR . Regulation of TNF-mediated cell death and inflammation by human adenoviruses Infect Agents Dis 1994 3: 106–115
Kirn D et al. Adenovirus E1A CR2 mutants as selectively-replicating agents for cancer Cancer Gene Ther 1998
Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 2000 19: 2–12
Hawkins L et al. Replicating adenoviral gene therapy Proc Am Assoc Cancer Res 1999 40: 476 (Abstr.)
Freytag SO et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy (see comments) Hum Gene Ther 1998 9: 1323–1333
Wildner O, Blaese RM, Morris JM . Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase Cancer Res 1999 59: 410–413
Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene Cancer Res 1994 54: 5745–5751
Roelvink P et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571
Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ . In situ cytokine gene transfection using vaccinia virus vectors Semin Oncol 1996 23: 88–100
Low K et al. Lipid A mutant salmonella with suppressed virulence and TNF-alpha induction retain tumor-targeting in vivo Nat Biotechnol 1999 17: 37–41
Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with head and neck cancer Cancer Res 2000 60: 6359–6366
Heisse C, Kirn D . Combination therapy with a replication-selective adenovirus and cisplatin chemotherapy; dependence on sequencing but independence from p53 gene status or route of administration Clin Cancer Res (in press)
Ries S et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (Onyx-015) Nature Med 2000 6: 1128–1133
Acknowledgements
The following individuals have been instrumental in making this manuscript possible: John Nemunaitis, Stan Kaye, Tony Reid, Fadlo Khuri, James Abruzzesse, Eva Galanis, Joseph Rubin, Antonio Grillo-Lopez, Carla Heise, Larry Romel, Chris Maack, Sherry Toney, Nick LeMoine, Britta Randlev, Patrick Trown, Fran Kahane and Margaret Uprichard.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirn, D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 8, 89–98 (2001). https://doi.org/10.1038/sj.gt.3301377
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301377
Keywords
This article is cited by
-
A bibliometric review of oncolytic virus research as a novel approach for cancer therapy
Virology Journal (2021)
-
Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy
Molecular Cancer (2020)
-
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
Nature Communications (2017)
-
Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth
Molecular Therapy (2016)
-
Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice
Journal of Experimental & Clinical Cancer Research (2015)